Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 1

Interventions

Cyclophosphamide 8Biopsy 8Specimen Handling 7Magnetic Resonance Spectroscopy 6fludarabine 5ruxolitinib 4Vincristine 4X-Rays 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Cytarabine 310-propargyl-10-deazaaminopterin 3sodium-iodide symporter 2pembrolizumab 2duvelisib 2cemiplimab 2Prednisone 2Photons 2Methotrexate 2Immunoglobulin G 2Hydrocortisone 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Doxorubicin 2Disulfides 2Dexamethasone 2Calcium Dobesilate 2Azacitidine 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell × Depsipeptides × Clear all
NCT03161223 2022-03-31

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

University of Virginia

Phase 1/2 Recruiting
148 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡